Published in Gastroenterology on March 01, 1993
Evolution of liver transplantation. Hepatology (1982) 19.54
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow. Surg Gynecol Obstet (1960) 11.73
HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Induction of immunological tolerance by porcine liver allografts. Nature (1969) 5.89
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Successful small-bowel/liver transplantation. Lancet (1990) 4.85
Kidney transplantation in modified recipients. Ann Surg (1962) 4.66
Homotransplantation of multiple visceral organs. Am J Surg (1962) 4.28
IMMUNOSUPPRESSION AFTER EXPERIMENTAL AND CLINICAL HOMOTRANSPLANTATION OF THE LIVER. Ann Surg (1964) 4.14
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Principles of solid-organ preservation by cold storage. Transplantation (1988) 3.79
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
One-stage homotransplantation of the liver following total hepatectomy in dogs. Transplant Bull (1959) 3.62
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
A new method for one-stage hepatectomy for dogs. Surgery (1959) 3.11
The physiological response of the small bowel of the dog to ischemia including prolonged in vitro preservation of the bowel with successful replacement and survival. Ann Surg (1959) 3.10
Transplantation of stomach, intestine, and pancreas: experimental and clinical observations. Surgery (1967) 2.49
Simple hypothermic preservation for transporting human livers long distances for transplantation. Report of 12 cases. Transplantation (1977) 2.08
MASS HOMOTRANSPLANTATION OF ABDOMINAL ORGANS IN DOGS. Surg Forum (1960) 1.74
Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. Hepatology (1991) 1.30
Small bowel transplantation. World J Surg (1985) 0.89
Two and one-half-year follow-up after isolated cadaveric small bowel transplantation in an infant. Transplant Proc (1992) 0.77
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg (1987) 2.11
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04